The Philippine Academy of Rehabilitation Medicine (PARM) celebrated its 50th anniversary during its 35th annual convention, held alongside the 9th ASEAN Rehabilitation Medicine Association Conference at the Manila Hotel in Manila.
The event underscored the Philippines’ role in rehabilitation medicine and its contributions to the global medical community.
PARM president Jerico Dela Cruz said the country’s rehabilitation programs and medical training are globally competitive.
“Filipinos no longer need to seek rehabilitation treatment abroad, as our programs match global standards,” Dela Cruz said.
“Filipino doctors are often preferred for their expertise, compassion and renowned hospitality.”
Teresita Joy Evangelista, a professor at the University of the Philippines College of Medicine, noted the rapid growth of rehabilitation medicine in the Philippines.
“In just three years, the number of specialists has doubled, fueled by the rise of training institutions, growing interest in the field, and more doctors choosing rehabilitation medicine as a specialty,” Evangelista said.
She also cited the country’s international standing, saying its practices meet global standards and its members are frequently invited to lecture abroad.
The convention featured discussions on advancements in osteoporosis treatment, cognitive therapy, and the use of performing and visual arts as therapeutic tools.
Bonifacio Rafanan Jr., a past PARM president, and Roberto Mirasol, a past president of the Philippine College of Endocrinology, Diabetes, and Metabolism (PCEDM), presented on the latest management of post-fracture patients with postmenopausal osteoporosis.
Experts warned that osteoporosis could lead to three million fractures this year, incurring $25.3 billion in healthcare costs.
The Osteoporosis Society of the Philippines Foundation Inc. (OSPFI) estimates that by 2050, about 10.2 million Filipinos could be affected.
Mirasol discussed various osteoporosis treatments, including romosozumab, teriparatide, denosumab, alendronate, and bisphosphonates.
He highlighted a new treatment that stimulates bone formation and reduces bone resorption, offering hope to high-risk patients.
“This is a game changer for osteoporosis because it has shown compelling evidence of its effectiveness in boosting bone density and lowering fracture risk,” Mirasol said.
Rafanan presented case studies demonstrating the benefits of the new treatment for severe osteoporosis patients.
Dela Cruz also noted the government’s recognition of rehabilitation medicine’s importance, citing PhilHealth Memorandum Circular 2025-0003, which expands coverage for physical medicine, rehabilitation services, and assistive mobility devices.
Both Dela Cruz and Evangelista emphasized the need for more specialists to ensure equitable access to care nationwide. They encouraged more individuals to pursue the field.
Experts urged early detection and treatment for those with low bone density or high fracture risk.